Aragen Life Sciences Ltd. receives the 2024 Global Customer Value Leadership Award from Frost & Sullivan for Pioneering Excellence in Drug Discovery and Development Services

July 24, 2024 10:00 AM IST | By Cision
 Aragen Life Sciences Ltd. receives the 2024 Global Customer Value Leadership Award from Frost & Sullivan for Pioneering Excellence in Drug Discovery and Development Services
Image source: Kalkine Media

Aragen Life Sciences Ltd. excels in providing end-to-end drug discovery and development solutions, showcasing its innovative approaches and strong commitment to sustainability and customer satisfaction.

SAN ANTONIO, July 24, 2024 /PRNewswire/ -- Frost & Sullivan has recognized Aragen Life Sciences, a world-class contract research, development, and manufacturing organization (CRDMO), with the 2024 Global Customer Value Leadership Award. With nearly 25 years of experience, Aragen assists its global clients in various industries, such as pharmaceutical, biotech, and agrochemical, throughout the biopharmaceutical lifecycle, offering comprehensive solutions spanning small and large molecules.

The company provides highly customized services tailored to meet client requirements and leverages cutting-edge technologies, such as artificial intelligence and machine learning, to drive its discovery and development projects to commercialization.
The company provides highly customized services tailored to meet client requirements and leverages cutting-edge technologies, such as artificial intelligence and machine learning, to drive its discovery and development projects to commercialization.

The company provides highly customized services tailored to meet client requirements and leverages cutting-edge technologies, such as artificial intelligence and machine learning, to drive its discovery and development projects to commercialization.

It also focuses on sustainability through initiatives like carbon-neutral programs and green chemistry, underscoring its dedication to environmental responsibility.

Mani Kantipudi, CEO of Aragen Life Sciences, said, "We are honored to receive the 2024 Global Customer Value Leadership Award from Frost & Sullivan. This recognition reflects our relentless pursuit of excellence and innovation in delivering value to our clients. We remain committed to advancing the forefront of drug discovery and development while upholding the highest standards of quality and sustainability."

"Frost & Sullivan commends Aragen's impressive customer centricity, which is evident in its tailored approach to meeting diverse client needs, commitment to transparency and trust through collaborative partnerships, and dedication to ensuring customer satisfaction at every engagement stage. By adapting its strategies to address individual pain points, assigning dedicated product managers driven by customer feedback, and offering flexibility and choice in service delivery, Aragen sets itself apart as a leader in delivering exceptional customer experiences within the global life sciences industry," said Khushbu Jain, Principal Consultant at Frost & Sullivan.

Aragen's success is driven by a talented workforce of over 3,700 scientists worldwide, including 450+ PhDs, ensuring robust scientific capabilities and operational efficiency. The company's strategic investments and customer-centric approach have cemented its reputation as a trusted partner in the life sciences industry.

Each year, Frost & Sullivan presents this award to the company that demonstrates excellence in implementing strategies that proactively create value for its customers, focusing on improving the return on investment that customers make in its services or products. The award recognizes Aragen's unique focus on augmenting customer value beyond simple good service, leading to improved customer retention and an expanded base.

Frost & Sullivan Best Practices Awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Tarini Singh
P: +91- 9953764546
E: [email protected] 

About Aragen

Aragen Life Sciences is a leading R&D and manufacturing solutions provider to the global life sciences industries. It offers a range of solutions across the drug development continuum to advance small and large-molecule programs. The Company operates through a global network of eight sites with a team of ~4,400 employees and 450+ PhDs. Its expertise and experience have enabled over 400 customers to advance their research programs from early discovery through development and commercialization. Aragen's innovative mindset, infrastructure, flexible business models, clear purpose, and proprietary project management platform have enabled it to effectively scale and service large pharma, biotech, agrochemical, and animal health industries globally. Visit www.aragen.com for more details.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

Sponsored Articles


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.